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Key messages 
 The SDRNT1BIO is one of the largest and comprehensive collections of biomaterials 
from people with type 1 diabetes in existence.  
 The participants of the SDRNT1BIO have been shown to be broadly representative of 
all type 1 diabetes adults in Scotland across a range of characteristics. 
 Initial findings of note in the cohort are the low prevalence of renal complications in 
this contemporary cohort despite the low rate of achievement of glycaemic targets 
and the substantial socio-economic differentials in glucose self-management.  
 
 
Why was the cohort set up?   
Rationale for setting up the cohort 
Type 1 Diabetes Mellitus (T1DM) affects approximately 0.4-0.5% of the population.  A 70% 
increase in prevalent cases of type 1 Diabetes in those aged under 15 years in Europe 
between 2005 and 2020 is predicted.(1)  Despite advances in care, T1DM continues to be 
associated with substantial mortality, with an estimated current period life expectancy 
differential of on average 11-13 years.(2)  The main chronic complications include CVD, 
nephropathy, retinopathy and neuropathy.  Cardiovascular disease (CVD) continues to be 
increased 2-3 fold and diabetic kidney disease remains a major determinant of early 
mortality.(3) 
 
As detailed in the strategic plans of the main diabetes specific research funders, major 
research priorities in T1DM include a better understanding of the determinants of type 1 
and its complications including genetic determinants, improved methods for early detection 
of complications (www.diabetes.org.uk) and the development of sensitive biomarkers for 
complications (www.jdrf.org).  The availability of large prospective cohorts of patients, well 
characterised for complications, is pivotal to such research.  Accordingly we established the 
SDRNT1BIO to facilitate a wide range of research including, but not limited to the following;  
 
1. Discovery and validation of genetic determinants of type 1 diabetes 
Type 1 diabetes is partly genetically determined and more than 50 associated genetic loci 
have been identified with the HLA region on chromosome 6 having the major role.(4)  These 
genetic discoveries in T1DM have provided valuable insights on the potential pathways 
causing diabetes some of which are now being targeted by novel intervention therapies.  
They have also yielded useful data to aid the prediction of T1DM.  However, the 50+ 
discovered genetic loci for T1DM do not explain all of the known heritability for this disease 
with estimates of missing heritability varying from 20-80%.(5,6)  Among several potential 
explanations for this “missing heritability” are the existence of very rare variants with large 
effects and the existence of additional more common variants but with effects too low to 
have been detected by sample sizes used so far.  Existing studies used for discovering the 
genetics of T1DM have been based on up to ~12000 cases all combined which is many times 
lower than sample sizes in meta- analyses of GWAS data for T2DM.(4)  Of note almost all 
studies to date are in cohorts of childhood-onset T1DM specifically, despite the fact that 
almost 50% of T1DM has its onset in adulthood.  Indeed the largest study to date of older 
onset T1DM was limited to evaluation of already known loci in 1212 autoantibody positive 
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adults with diabetes in which subtle age of onset effects were found for some loci.(7,8)  
Other studies seeking age of onset effects have had very few people with age at diagnosis 
>30.  Thus additional discovery work to detect new T1DM loci are warranted especially for 
those with older age of onset.  Accordingly we are genotyping the SDRNT1BIO cohort.  We 
will conduct genome wide association studies using a background population representative 
control set of genotypes from Scotland and will then combine the resulting estimates of SNP 
associations with T1DM with the current published data to ascertain new T1DM associated 
loci.  An important feature of the collection is that we also know the phenotypic status for 
other auto-immune related conditions including coeliac disease and rheumatoid arthritis. 
 
2. Discovery and validation of genetic determinants of type 1 diabetes 
complications 
Many complications of diabetes are also heritable (20-50% for retinopathy and 
nephropathy) justifying attempts to discover their genetic determinants.(9)  Few 
unequivocal replicable genetic associations have been found so large scale initiatives are 
underway;  many of these have much greater focus on type 2 than type 1 diabetes because 
larger type 2 cohorts have been available since it is more prevalent (www.imi-summit.eu).  
However many of these phenotypes are more heterogeneous in T2DM than T1DM making 
discovery less tractable.  The Genie Consortium has focused on nephropathy specifically in 
T1DM and there is a JDRF funded wider consortium on genetics of nephropathy in T1DM 
that is currently underway.(10)  For many other phenotypes of relevance in type 1 diabetes 
efforts to discover genetic determinants are sparse.  So for example there is little genetic 
data on neuropathy,(11) propensity to hypoglycaemia or diabetic ketoacidosis or on 
persistent C-peptide secretion or blood pressure.  Thus the GWAS data from the SDRNT1BIO 
will augment existing international efforts on genetics of macro-and micro-vascular 
complications of diabetes and will provide novel GWAS studies of neglected traits relevant 
in T1DM. 
 
3. Pathogenesis and biomarkers of complications  
Several extremely productive prospective cohort studies of T1DM have yielded much of 
what we know about the pathogenesis and risk factors for complications and how these 
differ between type 1 and type 2 DM.  These include the EURODIAB PCS n=2787 (12), the 
Pittsburgh EDC n=658 (13), the DCCT/EDIC n=1300 (14), ORPS n=554 (15), and WESDR 
n=~1000 (16), CACTI n~656 (17), and FinnDiane n~4500 (18).  However, the total sample size 
and number of incident cases of complications across these cohorts does not provide 
optimal power for discovery efforts.  Other large cohort studies in T1DM such as the 
Swedish National Diabetes Register, use regular reporting of risk factors from clinical sites 
and linkage to routine data but do not currently have any sample collection.(19)  It is clear 
that to fully exploit new ‘omic methods for pathway and biomarker discovery, including 
lipidomics, metabolomics and genetics and to develop more precise prediction algorithms 
for complications that incorporate new biomarkers, further large cohorts of T1DM patients 
need to be laid down now in addition to the continued support of these existing excellent 
cohorts.  The creation of larger cohorts has been hampered by the logistical difficulties in 
obtaining repeated long term direct patient follow up in the many centres needed to create 
a large T1DM cohort.  Thus, with SDRNT1BIO, we decided to harness Scotland’s e-health 
care record system, and the existence of a unique health care identifier across all records in 
Scotland, to enable the creation of a cohort in which extensive prospective routine data are 
automatically captured. 
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4. Stratification of apparent T1DM 
The gold standard biomarker of endogenous insulin production are serum C-peptide 
concentrations.  Previously it was believed that all those with T1DM have no residual insulin 
secretion.  With the development of ultra-sensitive C-peptide assays, there is increasing 
realisation that detectable levels of C-peptide are much more common in T1DM than 
previously thought (20) with up to 75% of those with diabetes duration >5 years showing 
detectable levels and at least 8% having levels associated with reduced complications 
(>200pmol/L).(21,22)  This is of critical importance since it shows that the paradigm that 
T1DM is inevitably accompanied by complete beta-cell destruction is incorrect.  Specifically 
exploring the genetic and immunological differences between those with and without 
detectable C-peptide might yield possible mechanisms for preserving beta cell function and 
preventing or even reversing T1DM so this is another question being addressed by the 
SDRNT1BIO.  Also of interest is the role of residual insulin secretion in resistance to acute 
and chronic T1DM complications.(23) 
 
Another aspect of diabetes stratification is the improved detection of monogenic diabetes 
among those misdiagnosed as having T1DM.  Differentiating monogenic diabetes (hereafter 
MODY) from type 1 diabetes has important clinical consequences for patients with all with 
glucokinase gene mutations and most with HNF1A and HNF4A mutations able to come off 
insulin.(24)  However diagnosis of MODY remains difficult and at present it is estimated that 
only ~25 % of all MODY is diagnosed as such.(25)  Many potential MODY cases are never 
referred for sequencing.  Even when they are, the results of sequencing are not always 
interpretable unless a mutation that has been previously characterised as pathogenic or a 
new mutation of obvious functional effect is detected (a problem that will remain even 
when whole genome sequencing becomes widely used).  Several algorithms for improving 
detection have been proposed utilising clinical and family history, C-peptide status, auto-
antibody status, and sometimes other biomarkers such as C-reactive protein and glycan 
signatures so as to select those warranting sequencing at known MODY loci.(25)  Yet 
detection rates remain low.  About 2.9% of those diagnosed as T1DM under age 30 years 
will actually have MODY.  About half of misdiagnosed cases are initially diagnosed as T1DM.  
Only about 1% of MODY cases have de novo mutations.  Most affected individuals will 
therefore have relatives in the population who bear the same mutation on a haplotype 
inherited from a common ancestor.  Clinical course, family history data and known MODY 
status were collected in the SDRNT1BIO.  These data items will soon be augmented by 
genome wide SNP data, C-peptide and auto-antibody status.  Importantly the coverage 
fraction of the total population with apparent type 1 diabetes is 1/3 and we anticipate that 
1/6 of all misdiagnosed MODY in Scotland (n~125-150) cases are likely to have been 
sampled into the bioresource.  Together these data allow us to explore various strategies for 
improved detection of unidentified MODY cases.   
 
5. Environmental determinants of TIDM and complications including socio-
economic determinants  
The environmental determinants of type 1 diabetes remain largely unknown (putative 
factors include infection e.g. congenital rubella, caesarean section, older maternal age, 
Vitamin D deficiency etc.).(26)  Although prospective cohort studies with data pre-dating 
onset of diabetes are an ideal design for examining such factors, they are challenging with a 
disease of relatively low incidence such as T1DM.  Accordingly the approach used most 
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commonly has been the prospective study of first degree relatives of known cases of T1DM. 
Nonetheless with respect to T1DM aetiology the SDRNT1BIO can yield useful information on 
the role of environment in T1DM aetiology, especially by examining how the pattern of 
potential risk factors may vary with genotype or auto-antibody phenotype for example 
yielding insights into pathways.  Accordingly we have collected some lifestyle, environment 
and pre-diagnosis data by questionnaire.  For T1DM complications the SDRNT1BIO 
combined with the extensive e-health record data is being used to explore socio-economic 
differentials and the impact of health care activities on complications.  
 
Where is it located and how is it funded? 
The SDRNT1BIO was established with joint funding from the Chief Scientist Office and 
Diabetes UK.  The study activities including protocol development and recruitment of 
participants were overseen by a Study Steering Committee comprising representation from 
a patient representative, the study funders, and the lead diabetes consultants from ten 
participating Scottish Health Boards.  All data (baseline and prospective) are held at the co-
ordinating centre, University of Dundee, Scotland UK. 
 
 
Who is in the cohort?  
Study Design, Entry criteria and Sampling Frame  
Eligibility criteria are summarised in Table 1.  We aimed to recruit a representative sample 
of all adults aged 16 years and upwards with a clinical diagnosis of type 1 diabetes or with 
monogenic diabetes (i.e. a diagnosis of Maturity Onset Diabetes of the Young –MODY) or 
with a diagnosis of latent auto-immune disease of adulthood.   
 
The SDRNT1BIO cohort was established using a cross-sectional design for the study 
fieldwork with recruitment primarily focused on 10 of 14 Health Board possible regions in 
Scotland.  The boards not targeted were due to the envisaged high cost per participant 
given the geographic location and low population density (i.e. the Shetland Orkney and 
Western Islands and Borders).  As shown in Table 2 compared to the national T1DM 
population the Type 1 Bioresource follows a broadly similar pattern with most recruits 
coming from the more populated boards but with somewhat fewer patients from Greater 
Glasgow & Clyde and Lanarkshire.   
 
At present very few people with T1DM in Scotland are managed solely in primary care.  
Therefore the sampling frame used was the comprehensive SCI-Diabetes electronic health 
care record in which >99% of patients are registered.  Recruitment was primarily carried out 
at diabetes outpatient clinics in participating boards with some additional recruitment in 
renal units as some end stage renal disease patients have lower attendance at diabetes 
clinics.  In addition GP based clinics were carried out at a few sites of high population 
density.  At participating clinics we systematically evaluated each clinic list for the 
subsequent week for eligibility and as many attending eligible patients as could be seen on 
the day were invited to take part on the day or at a subsequent clinic visit.  There was 
sufficient research nurse time for 78% (7593 / 9731) of all attending eligibles to be invited 
and of these 80.7% (6127 / 7593) participated.  No financial incentive for participation was 
offered with the exception of travel expenses if a visit outside a routine clinic visit was 
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needed. 
 
Representativeness  
Table 3 shows the distribution of some key characteristics among the SDRNT1BIO recruits 
compared to the total distribution in the national registry from SCI-Diabetes.  As shown the 
participants are very representative of the national population in almost all characteristics.  
With regard to socio-economic status 16% of cohort participants are from areas with the 
most deprived Scottish Index of Multiple Deprivation compared to 20% of the total national 
T1DM population.  
 
 
What has been measured? 
Baseline data collection took place between 1 December 2010 and 29 November 2013 
inclusive, and comprised a single study visit, of approximately 30 minutes which took place 
at a hospital or primary care diabetes clinic.  Informed consent was documented for all 
participants and all samples.  Participants were asked to complete a self-report 
questionnaire, and had clinical measures and a blood sample taken.  Additionally patients 
were asked to provide a urine sample at the clinic visit and were provided a sample tube to 
post back a second urine sample later.  Table 4 summarises the items collected.  The current 
residential location of the participant was geocoded at the datazone level and its area 
Scottish Index of Multiple deprivation recorded.  
 
For the questionnaire items we attempted to use established validated instruments where 
these were available.  Accordingly we include the physical activity questions from the 
International Physical Activity Questionnaire (IPAQ).(27)  We used the established questions 
from the Michigan Neuropathy Scale that has been widely used.(28).  Acute crises were 
captured based on report of diabetic ketoacidosis and hypoglycaemic events in the past 12 
months and included a measure of hypoglycaemic awareness.(29)  The Hospital Anxiety and 
Depression Scale questionnaire was used.(30) 
 
For physical examination we captured two sitting blood pressure readings after five minutes 
of sitting quietly using the OMRON digital BP monitor or equivalent that has been validated 
by the British Hypertension Society.  Weight and height were measured using the existing 
scales and stadiometers of each clinic.  Bioimpedance measurements were obtained using 
the Tanita Body Composition Analyser BC-420MA or BC-418MA.  Waist and hip 
measurements were taken using a protocol based on guidance published by the Scottish 
Diabetes Research Network.(31) 
 
Blood samples obtained from participants were processed at the end of each clinic and 
aliquoted then frozen.  The time elapsed between sampling and freezing at -80oC was 
recorded.  The median and interquartile range for time to freezer was 2 hrs 15 mins  (1 hr 30 
mins – 3hrs 10 mins).  Samples were then periodically shipped on dry ice to the central 
laboratory where DNA was extracted and samples banked.  
 
 
Frequency of follow up 
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A key aim in setting up the cohort was to harness the potential of data linkage to routine 
electronic health care records as a means of follow up of participants.  Such linkage is 
feasible in Scotland because all health care records are a unique health care identifier, the 
Community Health Index (CHI) number.  This is assigned at birth or for those immigrating 
into Scotland on registration with a general practitioner (all health care is free at the point 
of delivery so almost all residents register with a general practitioner).  Such linkage can 
capture both retrospective and prospective data.  In the SDRNT1BIO all participants 
consented to such linkage.  Study day data have therefore been linked to extensive records 
specifically: 
 
1) SCI-Diabetes which captures over 99% of patients with diabetes in Scotland and contains 
key clinical encounters for diabetes related care including primary care, retinopathy 
screening, foot screening and issued prescriptions.  National coverage was obtained 
from 2004.  Blood and urine test results are also captured, being fed from SCI-STORE a 
Scotland wide federated database from NHS laboratories.  
2) The Scottish Renal Registry that captures data on all those in receipt of renal 
replacement therapy since 1960  
3) Routine  Data from Information Services Division (ISD) Scotland: 
a) Outpatient attendance (from 1997) 
b) Hospital Admissions & Discharges (from 1981) 
c) Birth outcomes including infant mortality and stillbirths (from 1997) 
d) Scottish Cancer Registry (from 1958)  
e) Deaths (from study day participation onwards)  
 
To date, linkages have been performed at baseline in 2013 and refreshed to include data up 
to end of 2014.  The prospective data linkages are ongoing with annual linkages planned for 
the foreseeable future.  By the end of 2014 it was possible to determine that 118 (1.2%) 
participants were already deceased.  The % of participants on whom linkage data have been 
obtained is sought is 100%.  Participants are considered to have become unobservable 
(through emigration or death) if at least 1 year has elapsed without any HbA1c or 
prescription records or if they have been de-registered at their general practice without re-
registration.  To date there are 59 such persons (0.96%).  
 
At recruitment participants were invited to give consent for future face-to-face follow up, to 
which 93% agreed; as yet we have not taken up this opportunity.  In addition, participants 
were invited to give consent for having spare blood captured and stored from any future 
clinical encounters, to which 94% of participants agreed.  We have established a mechanism 
for such a spare blood capture for the participants in two of the health board areas and plan 
to roll out nationally as part of the GoSHARE Spare Blood Project 
(http://www.goshare.org.uk/).  To date there are 224 patients for whom we now hold 
follow-up EDTA plasma.   
 
 
Initial findings of interest  
We intend this cohort description to be the first publication from the cohort.  Here we 
include some initial observations on glycaemia that have policy relevance.  
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Glycaemic management by sex and social class 
Management of type 1 diabetes has changed in recent years with moves towards more 
frequent bolus in basal bolus insulin regimes, use of pumps, more frequent blood glucose 
self-testing and carbohydrate counting.  Current data on the uptake of these more intensive 
self-management practices is lacking.  Here we describe the patterns of insulin management 
and glucose management among the SDRNT1BIO participants and examine associations 
with gender and socio-economic status.  Socio-economic status was assessed using the 
Scottish Index of Multiple Deprivation (SIMD) based on address at time of interview divided 
into quintiles.  Three measures of self-reported insulin and glucose management were 
analysed: 
 
• Insulin Frequency (IF) : <4 or ≥ 4 injections a day or using pump 
• Blood Glucose (BG) testing : <4 or ≥ 4 tests a day  
• Carbohydrate Counting or exchanges (CC) :  yes/no. 
 
We found that overall 73% (n=4316) were injecting at least four times daily (IF ≥4) but just 
4.6% (n=269) were using a pump (Table 5).  Overall 52% (n=3055) were testing blood 
glucose at least four times daily (BG ≥4) and 61% (n=3552) were using carbohydrate 
counting or exchange (CC).  Men had lower rates than women of IF ≥4 (71% vs. 76%), pump 
use (2.7% vs 6.9%), BG ≥4 (48% vs 57%), and CC (56% vs 68%), age adjusted p-values all 
<0.001.  All measures varied widely by SIMD.  Age-sex adjusted Odds Ratio (OR) 95% CI per 
unit increase in SIMD quintile was 1.15 (1.10-1.20) for IF ≥4 ; 1.32 (1.20-1.45) for pump use, 
1.11 (1.07-1.16) for BG ≥4, 1.22 (1.17-1.27) for CC, (p<0.001 for all) (Table 6).  All three 
measures (IF, BG and CC) measures were associated with lower mean HbA1c (Table 7).  
HbA1c was significantly lower in those in the more affluent areas (beta regression 
coefficient per SIMD quintile -0.16, p<0.0001 adjusted for age and sex, beta -0.13 on 
adjustment for glucose management).  We conclude that structured patient education 
programmes aimed at improving self-management, as recommended in our national 
diabetes strategy, need to explicitly tackle inequalities by sex and deprivation. 
 
 
What are the main strengths and weaknesses? 
The main strengths of the SDRNT1BIO cohort are i) its large size ii) the comprehensive 
retrospective and prospective capture of a wide range of health data iii) the large set of 
biosamples obtained iv) that the cohort is being comprehensively genotyped v) its 
demonstrable representativeness of the national adult population with type 1 diabetes vi) 
the high rate of consent to future follow up vii) the high rate of consent to spare blood 
capture viii) the low cost of the work given the amount of data collected.  Weaknesses are i) 
only a subset have follow up biosamples as yet ii)  lack of funding to date for re-examination 
and improving discoverability and infrastructure support for collaborative use. 
 
 
Can I get hold of the data? Where can I find out more? 
The study was carried out in accordance with the ethical principles in the Declaration of 
Helsinki and was approved by the Tayside Research Ethics Committee (Reference 
10/S1402/43) and the biosamples are held under the governance of the Tayside Tissue 
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Bank.  The data linkages are approved by the National Caldicott Guardians (References: 
2013/009; 2013/0014), Privacy Advisory Committee (Reference 15/13), NHS Central Register 
(NHSCR), and the Scottish Renal Registry. 
 
The SDRNT1BIO was established to support collaborative research use.  We aim to achieve 
the appropriate balance between fostering use and maintaining the data governance and 
security of linked data.  All data are held in an anonymised form with the linker file linking 
study identifier to identifiable details held separately and unavailable to researchers.  Data 
are held on a secure server accessible only to approved researchers.  Analysis takes place on 
the server with access via end-to-end encrypted secure shell tunneling.  Analysts must have 
undertaken an approved data security course.  A data access committee oversees 
application for collaboration.  
 
To date biosamples have been used for DNA extraction and genome wide genotyping.  
Serum samples have been used for the measurement of C-peptide, serum creatinine, auto-
antibodies (GAD, ZnT8, IA2) and for N- glycome analysis.(32)  The results of these are 
awaited.  Urine samples have been used for measurement of albumin:creatinine ratio.  
These studies represent collaborations with researchers in the United States, Croatia, 
Finland, Scotland, and the rest of the United Kingdom.  Interested collaborators should 
contact the study coordinator in the first place for access forms (via 
h.colhoun@dundee.ac.uk).  
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Profile in a nutshell 
• The SDRNT1BIO is one of the largest and most comprehensive collections of biomaterials 
from people with type 1 diabetes (T1DM) in existence, and has been shown to be 
representative of the national adult population with T1DM. 
• 6127 adults, aged 16 years or older, with T1DM, were recruited from across Scotland 
between 1 December 2010 and 29 November 2013, with a high rate of consent to future 
follow-up. 
• Biosamples include baseline collections of serum, plasma, whole blood and urine, 
alongside follow-up capture of plasma where patients consented to spare blood capture. 
• Baseline data includes sociodemographics, details of diabetes diagnosis and treatment, 
history of complications and lifestyle assessment, e.g. physical activity, smoking and alcohol 
aspects, alongside results from physical measures, e.g. anthropometry, bioimpedance 
and blood pressure. 
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• Data linkage to routine electronic health care records has allowed retrospective and 
prospective data capture across a number of health outcomes including: diabetes-related 
care in primary care; renal replacement therapy; outpatient attendance; hospitalizations; 
cancers; and deaths. The SDRNT1BIO has also been comprehensively genotyped. 
• SDRNT1BIO was established to support collaborative research use; access forms are 
available from the study coordinator [Helen.Colhoun@igmm.ed.ac.uk]. 
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Table 1. Inclusion and exclusion criteria for participation in SDRNT1BIO cohort 
Inclusion criteria main study 
(1) Male or female 
(2) 16 years of age or over 
(3) Not currently pregnant 
(4) Able to give informed consent 
(5) A label of type 1 diabetes, MODY or LADA on SCI-DC database or in clinical record 
(6) Interval between diagnosis and starting insulin <1 year for patients with diagnosis of 
type 1 diabetes 
(7) Current use of insulin if diagnosed with Type 1 diabetes 
 
Exclusion criteria for main study and MODY sub-study 
(1) Known secondary basis for diabetes e.g. haemochromatosis, pancreatitis, 
pancreatectomy  
 
 
Table 2. Health boards in order of contribution to Scottish wide population with T1DM 
 Type 1 Bioresource 
participants (N=6127) 
National T1DM population 
(N= 24552) 
 N, percent (SE) N, percent (SE) 
Greater Glasgow & Clyde 949, 15.50 (0.014) 5327, 21.70 (0.003) 
Lothian 1592, 26.00 (0.012) 3900, 15.89 (0.003) 
Lanarkshire 407, 6.65 (0.015) 2816, 11.47 (0.004) 
Grampian 749, 12.23 (0.014) 2679, 10.91 (0.004) 
Ayrshire & Arran 113, 1.85 (0.016) 1782, 7.26 (0.004) 
Fife 699, 11.41 (0.014) 1759, 7.16 (0.004) 
Tayside 937, 15.30 (0.014) 1716, 6.99 (0.004) 
Highlands 176, 2.87 (0.016) 1481, 6.03 (0.004) 
Forth Valley 243, 3.97 (0.016) 1453, 5.92 (0.004) 
Dumfries & Galloway 231, 3.77 (0.016) 737, 3.00 (0.004) 
Borders 18, 0.29 0.016) 512, 2.09 (0.004) 
Western Isles, Orkney and Shetland 12, 0.20 (0.001) 390, 1.59 (0.001) 
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Table 3a Comparison of SDRNT1BIO participants with national Scottish population with Type 
1 Diabetes (continuous variables) 
 
Characteristic 
Type 1 Bioresource participants (N=6127) National T1DM population (N=24552) 
N, Mean (SD) 
Median  
(25th,75th percentile) N, Mean (SD) 
Median  
(25th,75th percentile) 
Age at entry, y 6127, 44.8 (14.8) 45.1 (33.1,55.5) 24552, 43.3 (15.6) 42.9 (30.9,53.9) 
Diabetes duration, y 6127, 21.5 (13.5) 20.2 (10.8, 31.0) 24552, 20.7 (13.1) 18.9 (10.4,29.8) 
Age at diagnosis, y 6127, 23.3 (14.1) 22.3 (12.0,32.0) 24552, 22.6 (13.3) 21.0 (12.1,31.0) 
HbA1c, mmol/mol 6103, 71.4 (16.9)] 69.0 (60.0,80.0) 22318, 73.1 (19.2) 70.3 (60.7,83.0) 
MDRD eGFR, 
ml/min/1.73m2 
5752, 89.2 (24.5) 88.7 (74.2,103.5) 20909, 89.1 (26.5) 88.3 (73.4,104.2) 
Systolic blood 
pressure, mmHg 
6094, 130.1 (16.9)  129 (119,140) 22515, 129.3 (17.1) 129 (118,140) 
Diastolic blood 
pressure, mmHg 
6094, 75.0 (10.2) 75 (68, 82) 22513, 74.6 (10.1) 75 (68,80) 
BMI, kg/m2 5637, 26.9 (4.6)  26.3 (23.7, 29.5) 21674, 27.1 (5.5) 26.4 (23.4,30.0) 
 
 
Table 3b. Comparison of SDRNT1BIO participants with national Scottish population with 
Type 1 Diabetes (categorical variables) 
Characteristic 
Type 1 Bioresource 
participants (N=6127) 
National T1DM population 
(N=24552) 
N, Percent (SE) N, Percent (SE) 
Female sex 2696, 44.0 (0.009) 10718, 43.7 (0.002) 
Diabetes duration ≥ 5 y 5440, 88.8 (0.002) 21793, 88.8 (0.000) 
Diabetes diagnosed at age 50  308, 5.03 (0.016) 892, 3.6 (0.004) 
Known MODY 29, 0.47 (0.016) N/A 
Known LADA 4, 0.07 (0.016) N/A 
SIMD quintile   
  1 (most deprived) 956, 15.8 (0.014) 4750 , 20.0 (0.003) 
  2 1021, 16.8 (0.014) 4807 , 20.3 (0.003) 
  3 1158, 19.1 (0.013) 4932, 20.8 (0.003) 
  4 1369, 22.6 (0.013) 4723, 19.9 (0.003) 
  5 (least deprived) 1562, 25.8 (0.012) 4515, 19.0 (0.003) 
History of diabetes related complications   
  Any retinopathy ever 4681, 77.4 (0.004) 17862, 77.1 (0.001) 
  Retinopathy at most recent screening 3832, 63.4 (0.006) 12777 , 55.1 (0.002) 
  Cardiovascular disease admission 473, 7.7 (0.015) 2212, 9.0 (0.004) 
  Ever received dialysis 73, 1.2 (0.016) 363, 1.5 (0.004) 
Albuminuric status   
  Normoalbuminuric 4605, 88.6 (0.002) 17578, 81.4 (0.001) 
  Microalbuminuric 449, 8.6 (0.018) 3196, 14.8 (0.004) 
  Macroalbuminuric 141, 2.7 (0.019) 823, 3.8 (0.004) 
Albuminuric status based on SDRNT1BIO 
samples (≥1 ACR reading) 
5839, 95.3 (0.00)  
SE, standard error of mean 
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Table 4. Summary of measures collected during baseline for SDRNT1BIO study population 
(2011-2013) 
 Variables 
Self-report 
questionnaire 
Demographic characteristics 
• Date of birth 
• Sex 
• Ethnicity 
• Location when diabetes diagnosed 
Family History of diabetes 
Diabetes & Clinical History 
• Date of diagnosis 
• Other health conditions including specific questions on 
coeliac, rheumatoid and other auto-immune conditions 
Glucose and Insulin management 
• Start of insulin therapy and current regime 
• Date insulin injections started 
• Current insulin dose 
• Carbohydrate counting/exchange 
• Glucose self monitoring 
Diabetes Acute crises 
• Ketoacidosis 
• Hypoglycaemia 
History of Diabetes complications 
• Kidney dialysis/transplant 
• Laser therapy to back of the eye 
• History of amputation 
• Complications affecting legs and/or feet 
• Diabetic neuropathy diagnosis  
• Michigan neuropathy scale  
• Hospital Anxiety and Depression Scale (HADS) – 14 items 
Lifestyle 
Alcohol units per week  
Smoking habits (cigarettes/cigars/pipes) 
• Current smoker, ex-smoker, non-smoker 
• Frequency / number times a day smoked 
• Age started to smoke 
Physical activity  
• Intensity over previous week – vigorous, moderate, walking, 
sitting 
• Duration of activity over previous 7 days 
• Typical daily duration (hours and minutes) 
Clinical 
measures 
Sitting Blood pressure 
Height  
Weight  
Waist Hip Ratio 
Bioimpedence 
Biosamples 
stored 
Blood – non-fasting (n=6005 persons with a sample) 
• Serum, Plasma, whole blood in EDTA, whole blood in Paxgene 
tubes  
Single urine sample (n=5839 persons with a sample) 
Two urine samples (n=4902 persons with 2 or more samples) 
18 
Table 5. Glucose management measures by age (years) and sex 
 Males     
16-24 25-49 50-74 ≥75 All ages 
n 344 1809 1214 64 3431 
HbA1c, 
mmol/mol 
77.3 (1.2) 71.94 (0.4) 68.4 (0.4) 66.8 (1.7) 71.1 (0.3) 
Insulin 
Frequency ≥4 
injections/day 
254 (78.9) 1330 (76.3) 743 (63.7) 21 (35.0) 2348 (71.3) 
Insulin pump 
use 
11 (3.4) 42 
(2.4) 
37 
(3.2) 
0 
(0) 
90 
(2.7) 
Blood 
Glucose ≥4 
tests/day 
124 (38.6) 832 (47.9) 589 (50.5) 27 (44.3) 1572 (47.0) 
Carbohydrate 
Counting 
181 (56.4) 983 (56.8) 616 (54.1) 30 (50.0) 1810 (55.7) 
      
 Females     
 16-24 25-49 50-74 ≥75 All ages 
n 302 1413 919 62 2696 
HbA1c, 
mmol/mol 
82.4 (1.3) 72.8 (0.5) 71.0 (0.5) 69.9 (1.9) 73.2 (0.4) 
Insulin 
Frequency ≥4 
injections/day 
233 (1.3) 1078 (79.0) 624 (71.4) 33 (54.1) 1968 (75.9) 
Insulin pump 
use 
18 (6.1) 115 (8.4) 46 
(5.3) 
0 
(0) 
179 (6.9) 
Blood 
Glucose ≥4 
tests/day 
151 (51.2) 775 (56.9) 519 (59.7) 38 (62.3) 1483 (57.3) 
Carbohydrate 
Counting 
189 (64.3) 964 (70.7) 568 (66.5) 21 (36.2) 1742 (67.8) 
Data shown is N (%) 
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Table 6.  Odds of Glucose Management Measures according to the Scottish Index of 
Multiple Deprivation 
Indicator 
Quintile of Scottish Index of Multiple Deprivation Least 
versus 
most 
deprived 
1 (most 
deprived) 
2 3 4 5 (least 
deprived) 
OR (95% CI) 
Insulin 
Frequency ≥4 
injections/day 
625 (69.3) 711 (73.3) 861 (77.8) 1099 (82.8) 1237 (81.2) 2.29 
(1.88,2.79) 
Insulin pump 
use 
13 (1.4) 30 (3.1) 53 (4.8) 87 (6.6) 81 (5.3) 4.08 (2.33, 
7.73) 
Blood 
Glucose ≥4 
tests/day 
408 (45.6) 464 (48.0) 572 (51.9) 715 (54.0) 864 (56.6) 1.53 
(1.29,1.81) 
Carbohydrate 
Counting 
422 (47.2) 543 (56.9) 687 (63.1) 866 (65.8) 997 (66.1) 2.31 
(1.94,2.74) 
Data is N (%) unless otherwise indicated; OR=odds ratio adjusted for age and sex, P<0.001 
for all indicators 
 
 
Table 7.  HbA1c by Glucose Management Measures adjusted for age and sex 
Indicator 
Yes 
Mean (SE) 
No 
Mean (SE) P-value 
Insulin Frequency ≥4 injections/day 8.66 (0.02) 8.69 (0.004) <0.001 
Insulin pump use 8.04 (0.07) 8.70 (0.02) <0.001 
Blood Glucose ≥4 tests/day 8.38 (0.03) 8.97 (0.03) <0.001 
Carbohydrate Counting 8.55 (0.02) 8.84 (0.03) <0.001 
 
